JP2017516802A5 - - Google Patents

Info

Publication number

JP2017516802A5

JP2017516802A5 JP2016569857A JP2016569857A JP2017516802A5 JP 2017516802 A5 JP2017516802 A5 JP 2017516802A5 JP 2016569857 A JP2016569857 A JP 2016569857A JP 2016569857 A JP2016569857 A JP 2016569857A JP 2017516802 A5 JP2017516802 A5 JP 2017516802A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

eribulin

pharmaceutically acceptable

acceptable salt

Prior art date

2015-05-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 33
• UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 17
• 229960003649 eribulin Drugs 0.000 claims 16
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 16
• 150000003839 salts Chemical class 0.000 claims 15
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 14
• 206010028980 Neoplasm Diseases 0.000 claims 12
• 206010006187 Breast cancer Diseases 0.000 claims 11
• 208000026310 Breast neoplasm Diseases 0.000 claims 11
• 229940079593 drug Drugs 0.000 claims 11
• 239000003814 drug Substances 0.000 claims 11
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 8
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 8
• 239000002246 antineoplastic agent Substances 0.000 claims 8
• 229960004117 capecitabine Drugs 0.000 claims 8
• 229910052697 platinum Inorganic materials 0.000 claims 8
• 239000003080 antimitotic agent Substances 0.000 claims 7
• 229960004679 doxorubicin Drugs 0.000 claims 7
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 7
• 229960002014 ixabepilone Drugs 0.000 claims 7
• 201000011510 cancer Diseases 0.000 claims 6
• 239000003795 chemical substances by application Substances 0.000 claims 5
• 238000002648 combination therapy Methods 0.000 claims 4
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
• 229930012538 Paclitaxel Natural products 0.000 claims 3
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 3
• 229960004562 carboplatin Drugs 0.000 claims 3
• 229960004316 cisplatin Drugs 0.000 claims 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
• 229960003668 docetaxel Drugs 0.000 claims 3
• 238000001802 infusion Methods 0.000 claims 3
• 238000001990 intravenous administration Methods 0.000 claims 3
• 229960001756 oxaliplatin Drugs 0.000 claims 3
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
• 229960001592 paclitaxel Drugs 0.000 claims 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
• 239000008177 pharmaceutical agent Substances 0.000 claims 2
• 230000004083 survival effect Effects 0.000 claims 2
• 102100038595 Estrogen receptor Human genes 0.000 claims 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
• 206010027476 Metastases Diseases 0.000 claims 1
• 102100025803 Progesterone receptor Human genes 0.000 claims 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 239000002552 dosage form Substances 0.000 claims 1
• 229960000439 eribulin mesylate Drugs 0.000 claims 1
• 108010038795 estrogen receptors Proteins 0.000 claims 1
• 230000009545 invasion Effects 0.000 claims 1
• 230000009401 metastasis Effects 0.000 claims 1
• 208000037819 metastatic cancer Diseases 0.000 claims 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 230000000394 mitotic effect Effects 0.000 claims 1
• 238000009099 neoadjuvant therapy Methods 0.000 claims 1
• 210000000056 organ Anatomy 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1
• 108090000468 progesterone receptors Proteins 0.000 claims 1
• 238000011084 recovery Methods 0.000 claims 1
• 238000001356 surgical procedure Methods 0.000 claims 1
• 208000024891 symptom Diseases 0.000 claims 1
• 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
• 230000004614 tumor growth Effects 0.000 claims 1